Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Amateur Traders Corner -- Ignore unavailable to you. Want to Upgrade?

To: Mama Bear who wrote (129)	8/2/2000 1:43:25 PM
From: Tom Hua	Respond to of 19633

Barb, thanks. Regards, Tom

To: Mama Bear who wrote (129)	8/2/2000 4:26:02 PM
From: Tom Hua	Read Replies (1) \| Respond to of 19633

ONYX-015 has to be injected directly into the tumour to work, meaning it is of no apparent use against tumours that are not easy to reach, or against tiny tumours that are not yet visible. The researchers said most of their patients eventually died of their cancer -- because other, untreated tumours in their body spread. Barb, so the bad news is the patients die anyway, the good news is they die with fewer tumors. That doesn't strike me as too comforting. Regards, Tom